1. Home
  2. CAC vs REPL Comparison

CAC vs REPL Comparison

Compare CAC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$46.42

Market Cap

781.2M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$7.17

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
REPL
Founded
1875
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
781.2M
692.8M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
CAC
REPL
Price
$46.42
$7.17
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$45.50
$11.13
AVG Volume (30 Days)
72.2K
1.4M
Earning Date
05-05-2026
02-03-2026
Dividend Yield
3.64%
N/A
EPS Growth
6.08
5.25
EPS
3.84
N/A
Revenue
$41,739,000.00
N/A
Revenue This Year
$19.15
N/A
Revenue Next Year
$6.05
N/A
P/E Ratio
$12.04
N/A
Revenue Growth
16.96
N/A
52 Week Low
$34.53
$2.68
52 Week High
$51.57
$13.24

Technical Indicators

Market Signals
Indicator
CAC
REPL
Relative Strength Index (RSI) 51.29 45.35
Support Level $42.36 $6.71
Resistance Level $46.86 $8.82
Average True Range (ATR) 1.07 0.46
MACD 0.15 0.01
Stochastic Oscillator 78.13 40.51

Price Performance

Historical Comparison
CAC
REPL

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: